D. Cerne

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
D Cerne, D. Cerne, Darko Cerne, Darko Černe
Publication record
48 papers · 554 citations · H-index 15

PAPERS

Diagnostics of Metabolic Bone Disease in Extremely Preterm Infants—Clinical Applicability of Bone Turnover Biochemical Markers and Quantitative Ultrasound
20242 citationsauthor #11
Farmacevtski terminološki slovar
20191 citationsauthor #15
Plasma Cathepsin S is Associated with High-density Lipoprotein Cholesterol and Bilirubin in Patients with Abdominal Aortic Aneurysms
20196 citationsauthor #3
Personalized laboratory medicine: a patient-centered future approach
201831 citationsauthor #2
Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease
201842 citationsauthor #6
The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet
201814 citationsauthor #3
The level of Cat S is increased and HDL-C is decreased at the same time in plasma of patients with abdominal aortic aneurysm and aortoiliac occlusive disease
20180 citationsauthor #4
Increased Plasma Cathepsin s at the Time of Percutaneous Transluminal Angioplasty is Associated with 6-months’ Restenosis of the Femoropopliteal Artery
20182 citationsauthor #7
Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease.
201838 citationsauthor #8
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
20174 citationsauthor #6
Correlations of Cathepsin S with lipoprotein subclasses levels and lipid parameters in patients with stable angina.
20170 citationsauthor #5
Advanced oxidation protein products (AOPPs) in lipoprotein subfractions in patients with different stages of renal disease.
20170 citationsauthor #6
Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/Timp-1 with Cardiovascular Risk in Renal Disease Patients.
201711 citationsauthor #6
P4 medicine and osteoporosis: a systematic review
20166 citationsauthor #3
The “Rise–Peak–Fall” Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats
20164 citationsauthor #3
Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients
201513 citationsauthor #7
The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA
20151 citationsauthor #10
Interrelated cathepsin S-lowering and LDL subclass profile improvements induced by atorvastatin in the plasma of stable angina patients.
20147 citationsauthor #10
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
20147 citationsauthor #4
Increased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival
201424 citationsauthor #6
Cell-free nucleic acids as a non-invasive route for investigating atherosclerosis.
201413 citationsauthor #1
Treatment With Low-dose Atorvastatin, Losartan, and Their Combination Increases Expression of Vasoactive-Related Genes in Rat Aortas
201316 citationsauthor #3
Lipoprotein lipase in non-small cell lung cancer tissue is highly expressed in a subpopulation of tumor-associated macrophages.
201321 citationsauthor #5
Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses.
20137 citationsauthor #10
Vasoactive-Related Genes in Rat Aortas Treatment With Low-dose Atorvastatin , Losartan , and Their Combination Increases Expression of
20130 citationsauthor #3
CTSS activation coexists with CD40 activation in human atheroma: evidence from plasma mRNA analysis.
20118 citationsauthor #1
Optimisation of methods for quantifying plasma mRNA levels from genes responsible for coronary artery plaque development and destabilization.
20114 citationsauthor #1
Increased DAPK1 but decreased CCL2 plasma levels of nucleic acids in patients with stable angina.
20112 citationsauthor #1
Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity.
201035 citationsauthor #1
Cell‐free DNA in the Peritoneal Effluent of Peritoneal Dialysis Solutions
201023 citationsauthor #7
Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis.
20107 citationsauthor #6
Increased lipoprotein lipase activity in non-small cell lung cancer tissue predicts shorter patient survival.
200921 citationsauthor #4
Investigation on identifying structural modes by sound pressure signals
20095 citationsauthor #2
Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients.
200817 citationsauthor #4
Optimization of Purification of Human Cell‐Free mRNA from Plasma
20087 citationsauthor #4
Standard citrate versus sequential citrate/anticoagulant-free anticoagulation during hemodialysis: a randomized trial.
200721 citationsauthor #3
LIPOPROTEIN LIPASE ACTIVITY AND GENE EXPRESSION IN LUNG CANCER AND IN ADJACENT NONCANCER LUNG TISSUE
200723 citationsauthor #1
Oxidative stress assays for disease risk stratification.
200612 citationsauthor #1
Renal functional reserve in patients with Type 1 diabetes mellitus
20045 citationsauthor #2
Sialic acid content of low-density lipoprotein in patients with coronary atherosclerosis and healthy subjects
20031 citationsauthor #1
Relationship between the Sialic Acid Content of Low-Density Lipoprotein (LDL) and Autoantibodies to Oxidized LDL in the Plasma of Healthy Subjects and Patients with Atherosclerosis
200217 citationsauthor #1
Early Detection of Chronic Complications: Diabetic Nephropathy
20020 citationsauthor #1
The First FESCC Continuous Postgraduate Course in Clinical Chemistry : New trends in classification, monitoring and management of diabetes mellitus
20020 citationsauthor #9
MILDLY ELEVATED SERUM CREATININE CONCENTRATION CORRELATES WITH THE EXTENT OF CORONARY ATHEROSCLEROSIS
200033 citationsauthor #1
Comparison of Laboratory Parameters as Risk Factors for the Presence and the Extent of Coronary or Carotid Atherosclerosis: the Significance of Apolipoprotein B to Apolipoprotein AII Ratio
200029 citationsauthor #1
The optimization of turnaround time for blood samples in an emergency clinical laboratory
19993 citationsauthor #3
Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience.
199811 citationsauthor #3
2.P.168 Low HDL cholesterol and low lipid standardized vitamin E are the best determinants of lipid risk in our coronary patients
19970 citationsauthor #2

TIMELINE

1997 0 citations

1998 11 citations

1999 3 citations

2000 62 citations

2002 17 citations

2003 1 citations

2004 5 citations

2006 12 citations

2007 44 citations

2008 24 citations

2009 26 citations

2010 65 citations

2011 14 citations

2013 44 citations

2014 51 citations

2015 14 citations

2016 10 citations

2017 15 citations

2018 127 citations

2019 7 citations

2024 2 citations

D. Cerne

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT